Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for the Treatment of Obesity and Weight-Related Comorbidities in Adolescents: A Randomized, Double-Blind, Placebo- Controlled Trial (SURMOUNT-ADOLESCENTS-2)
Latest Information Update: 01 Jun 2025
At a glance
- Drugs Tirzepatide (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Acronyms SURMOUNT-ADOLESCENTS-2
- Sponsors Eli Lilly and Company
Most Recent Events
- 24 Jul 2024 Status changed from not yet recruiting to recruiting.
- 05 Jun 2024 New trial record